Table 2.
Effect of ChEIs on Discontinuation, Efficacy, and Safety Outcomes in Patients with Alzheimer’s Disease
| Outcome | n | Effect size (95% CI) | I2 (%) |
|---|---|---|---|
| Discontinuation | |||
| All-cause discontinuation | 51 | OR = 1.66 (1.30, 2.03) | 51.7 |
| Discontinuation due to AEs | 44 | OR = 1.75 (1.45, 2.05) | 0 |
| Discontinuation due to LoE | 12 | OR = 0.56 (0.34, 0.78) | 0 |
| Efficacy | |||
| Cognitive function | 41 | SMD = 0.38 (0.28, 0.47) | 41.1 |
| Global change | 32 | SMD = 0.28 (0.22, 0.34) | 0 |
| Neuropsychiatric symptoms | 19 | SMD = 0.03 (-0.04, 0.09) | 0 |
| Functional capacity | 18 | SMD = 0.16 (0.11, 0.20) | 0 |
| Safety | |||
| Mortality | 19 | OR = 0. 65 (0.47, 0.83) | 0 |
| Proportion patients AEs | 34 | OR = 1.69 (1.46, 1.93) | 0 |
| Proportion patients SAEs | 32 | OR = 1.10 (0.84, 1.35) | 0 |
Abbreviations: AE, adverse event; LoE, Lack of efficacy; OR, odds ratio.